Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
Shannon N EddJavier CastañedaPratik ChoudharyRalf KolassaWinfried KeuthageJens KroegerCharles ThivoletMark L EvansRoseline RéJessica CellotSimona de PortuLinda VorrinkJohn ShinTim van den HeuvelOhad Cohennull nullPublished in: Diabetes, obesity & metabolism (2023)
ADAPT study phase glycaemic improvements were reproduced and sustained in the continuation phase, supporting the early adoption of AID therapy in people with type 1 diabetes not meeting glucose targets on MDI therapy.